Lobucavir

This classification denotes a purine antagonist and antiviral agent with the molecular formula C11H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8U5PYQ1R2E, chemically known as 9-(2,3-bis-(hydroxymethyl)-1-cyclobutyl)guanine but generally known as lobucavir, which bears US NIH Compound Identifier 60786. European Medicines Agency schedules Lobucavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08544MIG. The term LOBUCAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, No. 3, 1995, List 35). LOBUCAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lobucavir under HS 29335995 and SITC 51576. As of Q4 2014, LOBUCAVIR remains the US FDA Preferred Term for this commodity. Lobucavir bears US NLM identifiers UMLS ID C0651257 and NCI Concept Code C82253. SMILES: C1C(C(C1N2C=NC3=C2NC(=NC3=O)N)CO)CO.